-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KydOgCZnMmJ2G7oPylKQVUJyP35gbvvHJgv3ice5OmnPFNF6qdJXRYlvQFse9vV6 0QUt9PE6ruV8wqMUCGTTTA== 0000950116-03-002590.txt : 20030513 0000950116-03-002590.hdr.sgml : 20030513 20030513135600 ACCESSION NUMBER: 0000950116-03-002590 CONFORMED SUBMISSION TYPE: 10QSB PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20030331 FILED AS OF DATE: 20030513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIO MEDICA CORP CENTRAL INDEX KEY: 0000896747 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141702188 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10QSB SEC ACT: 1934 Act SEC FILE NUMBER: 000-28666 FILM NUMBER: 03694940 BUSINESS ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 BUSINESS PHONE: 8002271243 MAIL ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 10QSB 1 tenqsb.txt 10QSB SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-QSB [x] Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2003. [ ] Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPORATION ----------------------------------------------------------------- (Exact name of small business issuer as specified in its charter) New York 14-1702188 ------------------------------------------------------------------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 122 Smith Road, Kinderhook, New York 12106 ------------------------------------------- (Address of principal executive offices) 800-227-1243 --------------------------- (Issuer's telephone number) Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] State the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: 20,609,548 Common Shares as of May 13, 2003 Transitional Small Business Disclosure Format: Yes [ ] No [X] PART I FINANCIAL INFORMATION American Bio Medica Corporation Balance Sheets
March 31, December 31, 2003 2002 (Unaudited) ------------ -------------- Assets ------ Current assets: Cash and cash equivalents $ 309,000 $ 231,000 Accounts receivable, net of allowance of $70,000 at March 31, 2003 and December 31, 2002 1,335,000 1,105,000 Inventory 2,614,000 2,795,000 Prepaid and other current assets 116,000 60,000 ------------ -------------- Total current assets 4,374,000 4,191,000 Property, plant and equipment, net 1,390,000 1,457,000 ------------ -------------- Total Assets $ 5,764,000 $ 5,648,000 ============ ============== Liabilities and Stockholders' Equity ------------------------------------ Current liabilities: Accounts payable $ 867,000 $ 908,000 Accrued liabilities 649,000 513,000 Current portion of mortgages and notes payable and capital lease obligations 217,000 184,000 ------------ -------------- Total current liabilities 1,733,000 1,605,000 Long term portion of mortgages payable 668,000 673,000 Long term portion of unearned grant 50,000 50,000 ------------ -------------- Total liabilities 2,451,000 2,328,000 ------------ -------------- Stockholders' equity: Preferred stock; par value $.01 per share; 5,000,000 shares authorized; none issued and outstanding Common stock; par value $.01 per share; 50,000,000 shares authorized; 20,609,548 shares issued and outstanding at March 31, 2003 and December 31, 2002 206,000 206,000 Additional paid-in capital 17,788,000 17,788,000 Accumulated deficit (14,442,000) (14,435,000) Treasury stock (239,000) (239,000) ------------ -------------- Total stockholders' equity 3,313,000 3,320,000 ------------ -------------- Total liabilities and stockholders' equity $ 5,764,000 $ 5,648,000 ============ ==============
See accompanying notes to financial statements American Bio Medica Corporation Statements of Operations (Unaudited)
For The Three Months Ended March 31, ------------------------------- 2003 2002 -------------- ------------ Net sales $ 2,649,000 $ 2,208,000 Cost of goods sold 1,170,000 928,000 -------------- ------------ Gross profit 1,479,000 1,280,000 -------------- ------------ Operating expenses: Research and development 206,000 132,000 Selling and marketing 619,000 560,000 General and administrative 663,000 577,000 -------------- ------------ 1,488,000 1,269,000 -------------- ------------ Operating income/(loss) (9,000) 11,000 -------------- ------------ Other income (expense): Other income 12,000 27,000 Interest income 7,000 27,000 Interest expense (17,000) (11,000) -------------- ------------ 2,000 43,000 -------------- ------------ Income (loss) before provision for income taxes (7,000) 54,000 Provision for (benefit from) income taxes 0 0 -------------- ------------ Net income/(loss) attributable to common shareholders $ (7,000) $ 54,000 ============== ============ Basic and diluted income/(loss) per common share $ 0.00 $ 0.00 ============== ============ Weighted average shares outstanding - basic and diluted 20,609,548 20,609,548 ============== ============
See accompanying notes to financial statements American Bio Medica Corporation Statements of Cash Flows (Unaudited)
For The Three Months Ended March 31, ----------------------------------- 2003 2002 ------------------ --------------- Cash flows from operating activities: Net income/(loss) $ (7,000) $ 54,000 Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation 44,000 53,000 Non cash compensation expense 6,000 Accrued interest, related party (13,000) Gain on sale of land (30,000) Changes in: Accounts receivable (231,000) (494,000) Inventory 180,000 442,000 Prepaid expenses and other current assets (56,000) 18,000 Restricted cash 1,000 Accounts payable (41,000) (144,000) Accrued liabilities 136,000 (53,000) ------------ ------------- Net cash used in operating activities (4,000) (130,000) ------------ ------------- Cash flows from investing activities: Purchase of property, plant and equipment (96,000) (10,000) Sale of land 150,000 ------------ ------------- Net cash provided by/(used in) investing activities 54,000 (10,000) ------------ ------------- Cash flows from financing activities: Debt payments (5,000) (5,000) Capital lease payments (6,000) (5,000) Proceeds from line of credit 40,000 Line of credit payments (1,000) ------------ ------------- Net cash provided by/(used in) financing activities 28,000 (10,000) ------------ ------------- Net increase (decrease) in cash and cash equivalents 78,000 (150,000) Cash and cash equivalents - beginning of period 231,000 288,000 ------------ ------------- Cash and cash equivalents - end of period $ 309,000 $ 138,000 ============ ============= Supplemental disclosures of cash flow information Cash paid during year for: Interest $ 14,000 $ 11,000
See accompanying notes to financial statements Notes to financial statements (unaudited) March 31, 2003 Note A - Basis of Reporting The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items), which are considered necessary for a fair presentation of the financial position of American Bio Medica Corporation (the "Company" or "ABMC") at March 31, 2003, and the results of its operations, and cash flows for the three-month period then ended. The results of operations for the three-month period ended March 31, 2003 are not necessarily indicative of the operating results for the full year. These financial statements should be read in conjunction with the Company's audited financial statements and related disclosures for the year ended December 31, 2002 included in the Company's Form 10-KSB. During the year ended December 31, 2002, the Company earned net income of $719,000 from net sales of $10,312,000, and had net cash outflows from operating activities of $400,000. During the three months ended March 31, 2003, the Company sustained a net loss of $7,000 from net sales of $2,649,000, and had net cash used in operating activities of $4,000. The Company continued to take steps to improve its financial prospects including increased research and development expenditures, continued development of new products, continued evaluation of a potential "CLUB-DRUG" panel that could be a useful tool against the latest drugs of choice including Rohypnol, Ecstasy, Ketamine, Ritalin, GHB and Methamphetamine, entering into an agreement with an unrelated party to develop test components for an HIV test, and other measures to enhance profit margins. The Company's continued existence is dependent upon several factors, including its ability to raise revenue levels and reduce costs to generate positive cash flows, and to sell additional shares of the company's common stock to fund operations, if necessary. NEW ACCOUNTING STANDARDS In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 143, Accounting for Asset Retirement Obligation. SFAS No. 143 requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred. When the liability is initially recorded, an entity capitalizes a cost by increasing the carrying amount of the long-lived asset. Over time, the liability is accreted to its present value each period and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, an entity either settles the obligation for its recorded amount or incurs a gain or loss upon settlement. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. The adoption of this Statement did not have a material impact on the Company's financial statements. In July 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. SFAS No. 146 addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies Emerging Issues Task Force (EITF) Issue No. 94-3, Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring). This Statement is effective for exit and disposal activities initiated after December 31, 2002. The adoption of this Statement did not have a material impact on the Company's financial statements. In November 2002, FASB issued FASB Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, an interpretation of FASB Statement No. 5, 57, and 107 and Rescission of FASB Interpretation No. 34 ("FIN 45"). FIN 45 clarifies the requirements of SFAS No. 5, Accounting for Contingencies, relating to the guarantor's accounting for, and disclosure of, the issuance of certain types of guarantees. FIN 45 requires that upon issuance of a guarantee, the guarantor must recognize a liability for the fair value of the obligation it assumes under that guarantee. FIN 45 specifically excludes certain guarantee contracts from its scope. Additionally, certain guarantees are not subject to FIN 45's provisions for initial recognition and measurement but are subject to its disclosure requirements. The initial recognition and measurement provisions are effective for guarantees issued or modified after December 31, 2002. The disclosure requirements are effective for our annual financial statements for the year ended December 31, 2002. The Company has adopted the provisions of this statement, which did not have a material impact on its financial statements. In December 2002, the FASB issued SFAS No. 148, Accounting for Stock Based Compensation--Transition and Disclosure, an amendment to FASB Statement No. 123. This Statement amends SFAS No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement No. 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. Finally, SFAS No. 148 amends APB Opinion No. 28, Interim Financial Reporting, to require disclosure about those effects in interim financial reporting. For entities that voluntarily change to the fair value based method of accounting for stock-based employee compensation, the transition provisions are effective for fiscal years ending after December 15, 2002. For all other companies, the disclosure provisions and the amendment to APB No. 28 are effective for interim periods beginning after December 15, 2002. The following pro forma information gives effect to fair value of the options on the date of grant using the Black-Scholes option-pricing model with the following assumptions: dividend yield of 0%, volatility ranging from 84% to 85% for 2003 and 87% to 90% for 2002, risk free interest rates of ranging from 4.69% to 4.98% for 2003 and 4.98% - 6.04% for 2002, and an expected life of 10 years for both 2003 and 2002. The pro-forma net loss represents three months amortization of expense associated with the option grants.
Three months ended Three months ended March 31, March 31, 2003 2002 ------------------------ --------------------- Net Income/(loss): As reported $ (7,000) $ 54,000 Pro forma $ (189,000) $ (115,000) Basic and fully diluted income/(loss) per share As reported $ .00 $ .00 Pro forma $ (.01) $(.01)
In January 2003, the FASB issued FASB Interpretation No. 46, Consolidation of Variable Interest Entities ("FIN 46"). FIN 46 requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or entitled to receive a majority of the entity's residual returns or both. FIN 46 also requires disclosures about variable interest entities that a company is not required to consolidate but in which it has a significant variable interest. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003. The consolidation requirements apply to existing entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply in all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. The Company does not believe the adoption of this Statement will have a material impact on its financial statements. Note B - Net Income or Loss Per Common Share Basic net income or loss per share is calculated by dividing the net income or loss by the weighted average number of outstanding common shares during the period. No effect has been given to potential issuances of common stock including outstanding options and warrants in the diluted computation as of March 31, 2003 and 2002 respectively, as their effect would be anti-dilutive. Potential common shares outstanding as of March 31, 2003 and 2002:
March 31, 2003 March 31, 2002 -------------- -------------- Warrants 2,651,703 2,651,703 Options 5,670,000 4,983,250
Note C - Litigation The Company has no pending litigation as of the date of this report. Note D - Sale of Land On March 31, 2003 the Company sold approximately 85 acres of land at its Kinderhook headquarters for $150,000 recognizing a gain of $30,000. Note E - Reclassifications Certain items have been reclassified to conform to the current presentation. Item 2. Management's Discussion and Analysis or Plan of Operation MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2003 AND 2002 The following discussion of the Company's financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company's other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company's fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; and (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service. Critical accounting policies - ---------------------------- There have been no significant changes to the Company's critical accounting policies, which are included in the Company's 10KSB filing for the year ended December 31, 2002, during the three months ended March 31, 2003. Results of operations for the three months ended March 31, 2003 as compared to the three months ended March 31, 2002 - ------------------------------------- Net sales were $2,649,000 for the three months ended March 31, 2003 as compared to $2,208,000 for the three months ended March 31, 2002, representing an increase of $441,000 or 20.0%. Direct sales, telemarketing sales and international sales combined to contribute approximately $2,200,000 or 83.1% of the net sales for the quarter compared to $1,500,000 or 60.3% in the first quarter of 2002. During the three months ended March 31, 2003, the Company continued its extensive program to market and distribute its primary product lines, the Rapid Drug Screen(R) and Rapid One(R), in addition to its saliva based test, the Oralstat(R) and its recently developed Rapid Tec(R) series. The Company continued its program of rebuilding relationships with key distributors, and executed agreements with several new distributors, expanded its marketing, and began development of diagnostic tests or test components using immunoassay lateral flow technology to diversify its product line into the areas of veterinary medicine, mycotoxin detection, and tuberculosis. In addition, components for an HIV test are being developed for an unrelated party and new drugs of abuse tests are being explored. Management believes that sales from its urine based drug test kits and the OralStat saliva based test will continue to grow as a result of this focus on the core business and new sales will increase from new product development. Cost of goods sold for the three months ended March 31, 2003 was $1,170,000 or 44.2% of net sales as compared to $928,000 or 42.0% of net sales for the three months ended March 31, 2002 reflective of a more costly mix of products sold. The increase in cost of goods sold is commensurate with the increase in sales. Gross margins decreased from 58% to 55% primarily due to price adjustments to secure several large volume contracts for state and national government accounts as well as several large corporate accounts. The cost of labor and materials has remained relatively consistent and the Company continued its efforts to control the costs to produce their product. Operating expenses increased 17.3% to $1,488,000 in first three months of 2003 as compared to $1,269,000 in the same period in 2002. This increase is attributable to increased investment in research and development with the addition of a scientist and two technicians, investment in marketing with the hiring of a director of marketing and a part time assistant, and net increases in general and administrative expenses Management believes that the amount of selling, general and administrative costs may increase as the Company creates the necessary infrastructure to: achieve its worldwide drug test marketing and sales goals, continue its penetration of the direct sales market, reinforce its distributor based sales, and leverage new product initiatives. However, management has implemented programs to control the rate of increase of these costs to be more consistent with the expected sales growth rate of the Company. Research and development - ------------------------ Research and development ("R&D") expenses for the three months ended March 31, 2003 were $206,000 or 7.8% of net sales compared to $132,000 or 6.0% of net sales for the three months ended March 31, 2002. The increase in expense is primarily due to several new positions added to the R&D group during 2002 and the first quarter of 2003. A research scientist, along with two laboratory technicians were added in late 2002 and the first quarter of 2003. These resources were added as part of management's initiatives to: focus on new product development to meet the changing needs of the on-site drug of abuse testing market, continue evaluation of a potential "CLUB-DRUG" panel that could be a useful tool against the latest drugs of choice including Rohypnol, Ecstasy, Ketamine, Ritalin, GHB and Methamphetamine, develop test components for an HIV test currently under development by an unrelated party, and develop new uses of immunoassay lateral flow technology, specifically in the areas of veterinary medicine and mycotoxin detection. Management expects increases in R&D expenses as it explores new markets and uses for its immunoassay technology. Selling and marketing expense - ------------------------------ Selling and marketing expense was $619,000 in the first quarter of 2003, an increase of $59,000, from $560,000 in the three months in 2002. This increase is primarily due to the hiring of a director of marketing and marketing assistant in early 2003. This increased investment in marketing has been made to support the Company's other efforts in penetrating direct sales and reinforcing distributor sales. Increased spending in advertisement, promotion, sales literature and trade show attendance has been offset by savings in sales expense resulting from changes to the sales commissions plan in late 2002 and early 2003. General and administrative expense - ---------------------------------- General and administrative expense was $86,000 higher in the first quarter of 2003 than the same period in 2002. Total G&A expense in the first quarter of 2003 was $663,000 compared to $577,000 in the first three months of 2002. Contributing to this were increases in accounting fees, personnel expense and insurance costs offset by savings in legal fees and postage. LIQUIDITY AND CAPITAL RESOURCES AS OF MARCH 31, 2003 The Company's cash requirements depend on numerous factors, including product development activities, ability to penetrate the direct sales market, market acceptance of its new products, and effective management of inventory levels in response to sales forecasts. The Company expects to devote substantial capital resources to continue its product development, expand manufacturing capacity and continue research and development activities. The Company will examine other growth opportunities including strategic alliances and expects such activities will be funded from existing cash and cash equivalents, issuance of additional equity or debt securities or additional borrowings subject to market and other conditions. The Company believes that its current cash balances, and cash generated from future operations will be sufficient to fund operations for the next twelve months. If cash generated from operations is insufficient to satisfy the Company's working capital and capital expenditure requirements, the Company may be required to sell additional equity or obtain additional credit facilities. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all. The Company has working capital of $2,641,000 at March 31, 2003 as compared to working capital of $2,586,000 at December 31, 2002. The Company has historically satisfied its net working capital requirements through cash generated by proceeds from private placements of equity securities with institutional investors. The Company has never paid any dividends on its common shares and anticipates that all future earnings, if any, will be retained for use in the Company's business and it does not anticipate paying any cash dividends. Net cash used in operating activities was $4,000 for the three months ended March 31, 2003 compared to $130,000 for the three months ended March 31, 2002. The net cash used in operating activities for the three months ended March 31, 2003 was primarily due to and increase in accounts receivable of $231,000, resulting from increased sales, an increase in prepaid expenses of $56,000, primarily due to increased insurance costs, and a decrease in accounts payable of $41,000, partially offset by an a decrease in inventory of $180,000, resulting from increased sales and continued efforts to control inventory levels and an increase in accrued expenses of $136,000 resulting from increases in personnel costs and the timing of the quarter end in relation to scheduled payrolls. The net cash used in operating activities for the three months ended March 31, 2002 was primarily due to an increase in accounts receivable of $494,000, a decrease in accounts payable of $144,000, and a decrease of accrued expenses of $53,000, partially offset by net income of $54,000, and a decrease in inventory of $442,000. Net cash provided by investing activities was $54,000 for the three months ended March 31, 2003 compared to net cash used in investing activities of $10,000 for the three months ended March 31, 2002. The net cash provided by investing activities in the first quarter of 2003 was comprised of proceeds from the sale of approximately 85 acres of land at the Company's headquarters in Kinderhook, NY totaling $150,000, offset by $96,000 for the purchase of property, plant and equipment. The net cash used in investing activities in the first quarter of 2002 was for the purchase of property, plant and equipment. Net cash provided by financing activities was $28,000 for the three months ended March 31, 2003, consisting of capital lease and debt payments totaling $11,000 offset by proceeds from the Company's line of credit totaling $40,000. The net cash used in financing activities for the three months ended March 31, 2002 was for capital lease and debt payments totaling $10,000. At March 31, 2003 and 2002, the Company had cash and cash equivalents of $309,000 and $138,000, respectively. The Company's primary short-term capital and working capital needs relate to continued support of its research and development programs, opening new distribution opportunities, focusing sales efforts on segments of the drugs of abuse testing market that will yield high volume sales, increasing its manufacturing and production capabilities, and establishing adequate inventory levels to support expected sales. DISCLOSURE CONTROLS AND PROCEDURES On April 29, 2003, the Company's CEO and CFO reviewed the Company's disclosure controls and procedures. Based on this evaluation, the Company, including the CEO and CFO, have concluded that the Company's disclosure controls and procedures are adequate to ensure the clarity and material completeness of the Company's disclosure in its periodic reports required to be filed with the SEC. Additionally, based upon this most recent evaluation, we have concluded that there were no significant changes in internal controls or other factors that could significantly affect the internal controls of the company subsequent to the date of evaluation. PART II OTHER INFORMATION Item 1. Legal Proceedings: None Item 2. Changes in Securities None. Item 3. Defaults upon Senior Securities None. Item 4. Submission of Matters to a Vote of Security-Holders None. Item 5. Other Information None. Item 6. Exhibits and Reports on Form 8-K (a) Exhibits 99.1 Certification of the Chairman of the Board and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 99.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (b) Reports on Form 8-K On February 12, 2003, the Company filed a form 8-K related to the appointment of Daniel W. Kollin to the Registrant's Board of Directors. SIGNATURES In accordance with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMERICAN BIO MEDICA CORPORATION (Registrant) By: Keith E. Palmer ------------------------------------------- EVP of Finance, Chief Financial Officer and Treasurer (Principal Accounting Officer and duly authorized Officer) Dated: May 13, 2003 CERTIFICATIONS - -------------- I, Gerald A. Moore, certify that: 1. I have reviewed this quarterly report on Form 10-QSB of American Bio Medica Corporation; 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have: a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions): a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and 6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. Date: May 13, 2003 Gerald A. Moore --------------------------- Gerald A. Moore Chairman, CEO and President CERTIFICATIONS - -------------- I, Keith E. Palmer, certify that: 1. I have reviewed this quarterly report on Form 10-QSB of American Bio Medica Corporation; 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; 3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; 4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have: a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date; 5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions): a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and 6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. Date: May 13, 2003 Keith E. Palmer ------------------------- Keith E. Palmer Chief Financial Officer EX-99 3 ex99-1.txt EXHIBIT 99.1 EXHIBIT 99.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of American Bio Medica Corporation (the "Company") on Form 10-QSB for the period ending March 31, 2003 as filed with the Securities and Exchange Commission on May 13, 2003 (the "Report"), I, Gerald A. Moore, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Gerald A. Moore ------------------------- Gerald A. Moore Chairman of the Board and Chief Executive Officer May 13, 2003 EX-99 4 ex99-2.txt EXHIBIT 99.2 EXHIBIT 99.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of American Bio Medica Corporation (the "Company") on Form 10-QSB for the period ending March 31, 2003 as filed with the Securities and Exchange Commission on May 13, 2003 (the "Report"), I, Keith E. Palmer, Chief Financial Officer and Vice President of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Keith E. Palmer --------------------------- Keith E. Palmer Chief Financial Officer and Vice President May 13, 2003 -----END PRIVACY-ENHANCED MESSAGE-----